Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anjuli Luthra

Gastroenterology Tampa, FL Medical Doctor

NPI 1205192580 CMS profile 2582674

12902 Usf Magnolia Dr, Tampa, FL 33612

Open in the dashboard

General payments

$43,329

85 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anjuli Luthra of Tampa, FL is reported in the CMS Open Payments database as having received $43,329 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,846 30
2024 General $1,553 11
2023 General $5,303 16
2022 General $6,836 23
2021 General $791 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anjuli Luthra
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Anjuli Luthra were reported at $28,846. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Anjuli Luthra Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $791 $352 $106–$1,054 $132
2022 $6,836 $448 $129–$1,270 $149
2023 $5,303 $533 $150–$1,390 $160
2024 $1,553 $605 $160–$1,606 $164
2025 $28,846 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $33,472 68 payments
  2. Wilson Cook Medical Incorporated $6,070 2 payments
  3. Mauna Kea Technologies, Inc. $1,963 6 payments
  4. Ovesco Endoscopy USA, Inc. $544 1 payment
  5. Omega Medical Imaging, LLC $538 1 payment
  6. Medtronic, Inc. $484 4 payments
  7. Amgen Inc. $149 1 payment
  8. FUJIFILM Medical Systems USA, Inc. $85 1 payment
  9. Shield Therapeutics Inc $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,945 10 payments
  2. Consulting Fee $12,275 5 payments
  3. Food and Beverage $4,344 50 payments
  4. Travel and Lodging $3,965 19 payments
  5. Honoraria $1,800 1 payment
Products named General payments · program years 2021–2025
  1. General - Therapies $18,316 14 payments
  2. WallFlex Duodenal $7,777 5 payments
  3. Hemospray $6,070 2 payments
  4. General - EndoChoice $1,161 6 payments
  5. SpyGlass $1,083 10 payments
  6. EXALT Model D Exalt_Endo $724 9 payments
  7. EXALT Model D EXALT Model D_ENDO $525 5 payments
  8. Axios $262 2 payments
  9. General - Biliary Devices $208 3 payments
  10. NEXPOWDER $190 2 payments
  11. Other $715 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

107

Median for Gastroenterology: 569

Drug cost

$1,860

Median for Gastroenterology: $104,976

Branded share of claims

41.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 15 $1,019
Omeprazole Generic 36 $287
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 11 $246
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $214
Ciprofloxacin Hcl Generic 27 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$50,978

Medicare's payments for the services billed

Medicare patients

201

Average age 74

Services billed

447

99 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 48%
Ischemic heart disease 42%
Diabetes 34%
Chronic kidney disease 33%
Depression 25%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record